Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
Mult Scler
; 19(8): 1106-12, 2013 Jul.
Article
en En
| MEDLINE
| ID: mdl-23401129
ABSTRACT
BACKGROUND:
Limited information is available on the use of natalizumab (NA) in pediatric multiple sclerosis (ped-MS) patients.OBJECTIVE:
The purpose of this study was to describe the long-term effects of NA in a large cohort of active ped-MS patients.METHODS:
Patients with definite ped-MS were treated with NA if in the previous year they had experienced at least two relapses or a severe relapse with incomplete recovery while on immunomodulating treatment, or at least two relapses and new magnetic resonance imaging (MRI) lesions regardless of any prior treatment.RESULTS:
The study included 55 patients (mean age 14.4 years, mean number of relapses 4.4, pre-treatment mean disease duration 25.5 months). They received a median number of 26 infusions. Three relapses occurred during the follow-up, one female patient continued to deteriorate in cognitive functioning. Mean Expanded Disability Status Scale (EDSS) scores decreased from 2.7 to 1.9 at the last visit (p<0.001). During the follow-up the majority of patients remained free from MRI activity. Transient and mild clinical adverse events occurred in 20 patients. Mild hematological abnormalities occurred in seven patients. Anti-JCV antibodies were detected in 20/51 tested patients.CONCLUSIONS:
NA was well tolerated in all patients. A strong suppression of disease activity was observed in the majority of patients during the follow-up.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Esclerosis Múltiple Recurrente-Remitente
/
Anticuerpos Monoclonales Humanizados
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Child
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Mult Scler
Asunto de la revista:
NEUROLOGIA
Año:
2013
Tipo del documento:
Article
País de afiliación:
Italia